Korean J Urogenit Tract Infect Inflamm.  2015 Apr;10(1):31-35. 10.14777/kjutii.2015.10.1.31.

Risk Factors Analysis Related to Complications of Transrectal Ultrasound-Guided Prostate Needle Biopsy: The Influence of Asymptomatic Pyuria on Complications

• Jeon CH
• Jung W
• Ha JY
• Park CH
• Kim CI
• Kim BH

• KMID: 1839386
• DOI: http://doi.org/10.14777/kjutii.2015.10.1.31

Abstract

PURPOSE
In clinical settings, patients with asymptomatic pyuria were common undergoing transrectal ultrasonography prostate needle biopsy (TRUSBx). The purpose of this study was to analyze the effects of asymptomatic pyuria on the occurrence of complications of TRUSBx.
MATERIALS AND METHODS
A total of 1,054 patients underwent TRUSBx from January 2007 to December 2011. For these patients, complications, presence of asymptomatic pyuria, anti-coagulant usage, TRUSBx history, previous hospitalization within 1 month, prostate volume, diabetes, types of prophylactic antibiotics (quinolone or 3rd generation cephalosporin), and biopsy results were compared and analyzed.
RESULTS
Of 1,054 cases, 26 (2.5%) developed complications requiring treatment. Seven cases (0.7%) had gross hematuria, 10 cases (0.9%) had dysuria, 7 cases (0.7%) had acute urinary retention, and 2 cases (0.2%) had sepsis. Asymptomatic pyuria was shown in 353 cases (33.4%). Complication rate of asymptomatic pyuria cases was 4.2% compared with 1.6% for non-pyuria cases (p=0.011). Higher complication rate was also observed in cases with previous TRUSBx history (p<0.001), hospitalization within 1 month (p< 0.001), and diabetes (p<0.001). However prostate volume, use of anticoagulant, type of antibiotics, and presence of prostate cancer were not significantly different. In multivariate analysis, previous TRUSBx history, hospitalization within 1 month, and diabetes were statistically significant with higher complication rate.
CONCLUSIONS
A high incidence of complications was observed for previous TRUSBx history, hospitalization within 1 month, and diabetes. In univariate analysis, a high incidence of complications was observed for asymptomatic pyuria cases. Therefore, detailed caution is required for patients with such factors during TRUSBx.

Keyword

Prostatic neoplasms; Biopsy; Complications

MeSH Terms

Anti-Bacterial Agents
Biopsy
Biopsy, Needle*
Dysuria
Hematuria
Hospitalization
Humans
Incidence
Multivariate Analysis
Prostate*
Prostatic Neoplasms
Pyuria*
Risk Factors*
Sepsis
Ultrasonography
Urinary Retention
Anti-Bacterial Agents

Reference

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin. 2009; 59:225–49.

2. National Cancer Center, Korea Central Cancer Registry, Ministry of Health and Welfare. Annual report of cancer statistics in Korea in 2009. Seoul: Ministry of Health and Welfare. 2011.

3. Roberts RO, Bergstralh EJ, Besse JA, Lieber MM, Jacobsen SJ. Trends and risk factors for prostate biopsy complications in the pre-PSA and PSA eras, 1980 to 1997. Urology. 2002; 59:79–84.

4. Anastasiadis A, Zapała L, Cordeiro E, Antoniewicz A, Dimitriadis G, De Reijke T. Complications of prostate biopsy. Expert Rev Anticancer Ther. 2013; 13:829–37.

5. Rodríguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J Urol. 1998; 160:2115–20.

6. Miller J, Perumalla C, Heap G. Complications of transrectal versus transperineal prostate biopsy. ANZ J Surg. 2005; 75:48–50.

7. Enlund AL, Varenhorst E. Morbidity of ultrasound-guided transrectal core biopsy of the prostate without prophylactic antibiotic therapy. A prospective study in 415 cases. Br J Urol. 1997; 79:777–80.

8. Norberg M, Holmberg L, Häggman M, Magnusson A. Deter-minants of complications after multiple transrectal core biopsies of the prostate. Eur Radiol. 1996; 6:457–61.

9. Clements R, Aideyan OU, Griffiths GJ, Peeling WB. Side effects and patient acceptability of transrectal biopsy of the prostate. Clin Radiol. 1993; 47:125–6.

10. Berger AP, Gozzi C, Steiner H, Frauscher F, Varkarakis J, Rogatsch H, et al. Complication rate of transrectal ultrasound guided prostate biopsy: a comparison among 3 protocols with 6, 10 and 15 cores. J Urol. 2004; 171:1478–80.

11. Djavan B, Waldert M, Zlotta A, Dobronski P, Seitz C, Remzi M, et al. Safety and morbidity of first and repeat transrectal ultrasound guided prostate needle biopsies: results of a prospective European prostate cancer detection study. J Urol. 2001; 166:856–60.

12. Ecke TH, Gunia S, Bartel P, Hallmann S, Koch S, Ruttloff J. Complications and risk factors of transrectal ultrasound guided needle biopsies of the prostate evaluated by questionnaire. Urol Oncol. 2008; 26:474–8.

13. Pinkhasov GI, Lin YK, Palmerola R, Smith P, Mahon F, Kaag MG, et al. Complications following prostate needle biopsy requiring hospital admission or emergency department visits - experience from 1000 consecutive cases. BJU Int. 2012; 110:369–74.

14. Kakehi Y, Naito S. Japanese Urological Association. Complication rates of ultrasound-guided prostate biopsy: a nationwide survey in Japan. Int J Urol. 2008; 15:319–21.

15. Kim HJ, Kim YJ, Huh JS. The risk factors of urinary tract infection with fever after transrectal ultrasonography guided biopsy of prostate. Korean J Urogenit Tract Infect Inflamm. 2012; 7:36–42.

16. Rietbergen JB, Kruger AE, Kranse R, Schröder FH. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology. 1997; 49:875–80.

17. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Terry WJ, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 1990; 143:1146–52.

18. Aus G, Hermansson CG, Hugosson J, Pedersen KV. Transrectal ultrasound examination of the prostate: complications and acceptance by patients. Br J Urol. 1993; 71:457–9.

19. Sieber PR, Rommel FM, Agusta VE, Breslin JA, Huffnagle HW, Harpster LE. Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy. J Urol. 1997; 157:2199–200.

20. Taylor HM, Bingham JB. Antibiotic prophylaxis for transrectal prostate biopsy. J Antimicrob Chemother. 1997; 39:115–7.

21. Kim DH, Bae SR, Choi WS, Park HK, Paick SH, Kim HG, et al. The real practice of antibiotic prophylaxis for prostate biopsy in Korea where the prevalence of quinolone-resistant Escherichia coli is high. Korean J Urol. 2014; 55:593–8.

22. Gustafsson O, Norming U, Nyman CR, Ohström M. Complications following combined transrectal aspiration and core biopsy of the prostate. Scand J Urol Nephrol. 1990; 24:249–51.

23. Sanders A, Buchan N. Infection-related hospital admissions after transrectal biopsy of the prostate. ANZ J Surg. 2013; 83:246–8.

24. Shin BS, Hwang EC, Jung SI, Kwon DD, Park K, Ryu SB, et al. Clinical features of bacteremia caused by ciprofloxacin-resistant bacteria after transrectal ultrasound-guided prostate biopsy. Korean J Urogenit Tract Infect Inflamm. 2011; 6:61–6.

25. Aus G, Ahlgren G, Bergdahl S, Hugosson J. Infection after transrectal core biopsies of the prostate–risk factors and antibiotic prophylaxis. Br J Urol. 1996; 77:851–5.

26. Loeb S, van den Heuvel S, Zhu X, Bangma CH, Schröder FH, Roobol MJ. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol. 2012; 61:1110–4.

27. Ehdaie B, Vertosick E, Spaliviero M, Giallo-Uvino A, Taur Y, O'Sullivan M, et al. The impact of repeat biopsies on infectious complications in men with prostate cancer on active surveillance. J Urol. 2014; 191:660–4.

28. Nicolle LE. Asymptomatic bacteriuria in institutionalized elderly people: evidence and practice. CMAJ. 2000; 163:285–6.

29. Nicolle LE, Bradley S, Colgan R, Rice JC, Schaeffer A, Hooton TM. Infectious Diseases Society of America; American Society of Nephrology; American Geriatric Society. Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin Infect Dis. 2005; 40:643–54.

30. Liss MA, Peterson EM, Johnston B, Osann K, Johnson JR. Prevalence of ST131 among fluoroquinolone-resistant Escherichia coli obtained from rectal swabs before transrectal prostate biopsy. Urology. 2013; 81:548–55.